Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

2.

Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease.

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR.

J Neurosci. 2001 Dec 15;21(24):RC189.

3.

2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease.

Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, Satyamurthy N, Barrio JR.

Mol Imaging Biol. 2003 Nov-Dec;5(6):404-17. Review.

PMID:
14667495
4.

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013.

PMID:
20385246
5.

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR.

Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35.

PMID:
11790632
6.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
7.

[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, Chen PP, Cole GB, Jones MR, Huang SC, Flood DG, Trusko SP, Small GW, Cole GM, Barrio JR.

Neurobiol Dis. 2011 Sep;43(3):565-75. doi: 10.1016/j.nbd.2011.05.003.

8.

Visualizing pathology deposits in the living brain of patients with Alzheimer's disease.

Kepe V, Huang SC, Small GW, Satyamurthy N, Barrio JR.

Methods Enzymol. 2006;412:144-60. Review.

PMID:
17046657
9.

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.

Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM.

J Biol Chem. 2005 Feb 18;280(7):5892-901.

10.

PET of brain amyloid and tau in mild cognitive impairment.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.

N Engl J Med. 2006 Dec 21;355(25):2652-63.

11.

5-(2E,4E)-5-(6-hydroxy-4-oxo-2-thioxo-1,2,3,4-tetrahydroxy-5 pyrimidinyl)-2,4-pentadienylidene-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Jul 1 [updated 2012 Oct 25].

12.

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, Krautkramer MJ, Kung HF, Skovronsky DM, Hefti F, Clark CM.

Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):8-16. doi: 10.1097/WAD.0b013e31821300bc.

13.

Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain.

Okamura N, Suemoto T, Shimadzu H, Suzuki M, Shiomitsu T, Akatsu H, Yamamoto T, Staufenbiel M, Yanai K, Arai H, Sasaki H, Kudo Y, Sawada T.

J Neurosci. 2004 Mar 10;24(10):2535-41.

14.

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.

Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN.

J Nucl Med. 2009 Sep;50(9):1464-70. doi: 10.2967/jnumed.109.064360.

15.

Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies.

Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, Shipley NJ, Libri V, Lockhart A.

J Neurochem. 2009 Apr;109(2):623-30. doi: 10.1111/j.1471-4159.2009.05996.x.

16.

[Molecular imaging of beta-amyloid plaques in the brain].

Ono M.

Brain Nerve. 2007 Mar;59(3):233-40. Review. Japanese.

PMID:
17370649
17.

2-(4-(2-[18F]Fluoroethyl)piperidin-1-yl)benzo[4,5]imidazo[1,2-a]pyrimidine.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Sep 27 [updated 2012 Dec 12].

18.

The merits of FDDNP-PET imaging in Alzheimer's disease.

Shin J, Kepe V, Barrio JR, Small GW.

J Alzheimers Dis. 2011;26 Suppl 3:135-45. doi: 10.3233/JAD-2011-0008. Review.

PMID:
21971458
19.

Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.

Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP.

Nucl Med Biol. 2009 May;36(4):411-7. doi: 10.1016/j.nucmedbio.2009.01.013.

PMID:
19423009
20.

Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans.

Wardak M, Wong KP, Shao W, Dahlbom M, Kepe V, Satyamurthy N, Small GW, Barrio JR, Huang SC.

J Nucl Med. 2010 Feb;51(2):210-8. doi: 10.2967/jnumed.109.063701.

Items per page

Supplemental Content

Support Center